Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People’s Republic of China-Reference-Cited by-同舟云学术

Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People’s Republic of China

Published:2022-06 Issue:6 Volume:17 Page:816-826
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Lu Shun,Zhou Qing,Liu Xiaoqing,Du Yingying,Fan Yun,Cheng Ying,Fang Jian,Lu You,Huang Cheng,Zhou Jianying,Song Yong,Wang Kai,Pan Hongming,Yang Nong,Li Juan,Chen Gongyan,Chang Jianhua,Cui Jiuwei,Liu Zhe,Bai Chunxue,Zhang Helong,Zhao Huadong,Zhang Kaiting,Peltz Gerson,Li Heyan,Wu Yi-Long^ORCID

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference25 articles.

1. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues;Martelli;Am J Pathol,2009

2. Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer;Tiseo;Expert Rev Anticancer Ther,2011

3. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors

4. The continuum of care for ALK-positive NSCLC: from diagnosis to new treatment options - an overview;Solomon;Ann Oncol,2016

5. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann Oncol,2018

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New findings on the incidence and management of CNS adverse reactions in ALK-positive NSCLC with lorlatinib treatment;Discover Oncology;2024-09-13

2. Neurocognitive Adverse Events Related to Lorlatinib in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis;Cancers;2024-07-22

3. Case report: Precise NGS and combined bevacizumab promote durable response in ALK-positive lung adenocarcinoma with multiple-line ALK-TKI resistance;Frontiers in Oncology;2024-06-24

4. Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 1/2 Study;Journal of Thoracic Oncology;2024-06

5. Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK‐Positive Non‐small Cell Lung Cancer;Clinical Lung Cancer;2024-04